MedTrace Logo

Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD

NCT04257513 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-11-12

No results posted yet for this study

Summary

A 2-year clinical longitudinal study to measure plasma concentrations of 24S-hydroxycholesterol, a brain-derived cholesterol catabolite, in subjects with Huntington disease, from the presymptomatic to the symptomatic stages.

Conditions

  • Huntington Disease

Interventions

DIAGNOSTIC_TEST

Brain MRI

Neurological and Cognitive evaluation; Brain MRI

Sponsors & Collaborators

  • Istituto Di Ricerche Farmacologiche Mario Negri

    collaborator OTHER

  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2023-03-06
Completion
2023-06-02

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04257513 on ClinicalTrials.gov